Approval · Notice of Compliance 36794 · 2026
INFLUVAC: Notice of Compliance 36794
Issued January 27, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36794
- Date
- January 27, 2026
- Company
- BGP Pharma ULCEtobicoke, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Indication expansion: INFLUVAC (influenza vaccine, surface antigen, inactivated) is indicated for the prevention of influenza infection caused by the specific strains contained in the vaccine, in adults and children from 6 months of age and older.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| INFLUVAC | Not yet assigned | — |
Medicinal ingredients
- HAEMAGGLUTININ-STRAIN A(H1N1) 15 MCG per 0.5ML
- HAEMAGGLUTININ-STRAIN A(H3N2) 15 MCG per 0.5ML
- HAEMAGGLUTININ-STRAIN B 15 MCG per 0.5ML